It is reported that Beijing Puqi Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Puqi Pharmaceutical”) completed the A+ round of financing exceeding 100 million yuan in the third quarter, and completed the listing on the New Third Board on December 7, 2022 (stock code: 873969). The company’s capitalization process was further accelerated. The financing and listing will help the company to further promote multiple R&D projects and clinical projects, and at the same time support the company to improve the construction of small molecule design platform, characteristic multi-antibody macromolecule platform and preparation technology platform. This round of financing was led by Xianfeng Cowin, followed by Longpan Investment, Shanlan Capital, and Tongxi Management. Xingyuan Zhitong acted as the exclusive financial advisor in this transaction.
Founded in 2016, Puqi Pharmaceutical is an enterprise focusing on the R&D and industrialization of innovative drugs. Mr. Li Yuliang, the chairman of the company, has more than 20 years of experience in industrial operation management and investment; Dr. Du Yunlong, the CEO, has more than 20 years of work experience in famous multinational pharmaceutical companies such as Pfizer and GSK. Experience in the whole process of clinical trials, medical affairs, drug safety management and NDA listing.
The company has built technical platforms such as new drug design and discovery technology platform, biological evaluation platform for immunity and inflammation, clinical translational medicine platform for immune and inflammatory diseases, synthesis process research and development platform, quality management system and external drug preparation research and development platform. Complete technical capabilities from front-end to back-end clinical research and development.
Therapeutic areas focus on immune diseases that have not yet met clinical needs, including skin, ophthalmology, rhinology and other immune diseases, autoimmune diseases, inflammation and rare diseases; the company’s core product PG-011 is a selective small The molecular inhibitor is the first JAK multifunctional small molecule compound that enters the clinic and takes into account inflammation, immune regulation and tissue repair.
Puqi Pharmaceutical R&D pipeline
The representative of this round of investors, Dr. Xianfeng Qiyun Wang Yunhai, said, “The immune disease market is huge, and Puqi Medicine’s specialty products in the fields of skin, ophthalmology, and respiratory are expected to solve unmet clinical needs in this field and provide better solutions for related diseases. Therapeutic drugs. With its advanced technology development level, excellent innovation ability and rich management experience, we are firmly optimistic about the future development of Puqi Pharmaceutical.”
Dr. Wang Jiabao, senior vice president of Xingyuan Zhitong, said: “Puqi Pharmaceutical has both rigid R&D strength and has established a complete innovative drug industrialization system to realize effective management of the whole life cycle from R&D, quality to PV and real-world data. , excellent quality in terms of corporate operation management and commercialization potential, and we look forward to more progress from the company in the future.”
Editor: Dun Yuting
Further reading:
media reports
Tencent Technology Sohu 36Kr
related events
- Puqi Pharmaceutical completed the A+ round of financing exceeding 100 million yuan and completed the listing on the New Third Board2022-12-12
- Minowei Pharmaceutical completed the A-round financing of over 100 million yuan led by Huagai Capital2022-07-21
- Danuo Pharmaceutical completed the D round of financing of 264 million yuan2022-03-30
- Ruijian Pharmaceutical completed nearly 100 million yuan in A+ round financing2022-01-25
- The innovative company Bichen Pharmaceutical completed the B-round financing of US$30 million2022-01-04
This article is transferred from: https://readhub.cn/topic/8lGlcjGpc5e
This site is only for collection, and the copyright belongs to the original author.